Tuberculosis (TB) is still a major global health problem. One of the key gaps in TB control is the ability to diagnose TB accurately and early. There is about 4 million patients who are missed each year – closing the gap requires research, dedication and community awareness of TB.
UK Secretary of State for Foreign and Commonwealth Affairs Mr Boris Johnson visit’s MRC Unit The Gambia
Internationally recognised for its track record of research into tropical infectious diseases and the UK’s single largest investment in The Gambia, MRC Unit The Gambia (MRCG), will be visited for the very first time by United Kingdom (UK) Secretary of State for Foreign and Commonwealth Affairs, Mr Boris Johnson,
Download PDF in English Annual Report 2015: View online in English View online in French Download PDF in English Download PDF in French
Pfizer Receives European Approval for New Multi-Dose Vial Presentation of Prevenar 13 – conducted by MRC Unit The Gambia
On Wednesday, April 6, 2016, Pfizer announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) approved a new four-dose, multi-dose vial (MDV) presentation of Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]).
The launch of the MRC Unit The Gambia’s 2016-2021 Quinquennial (5-year strategic plan) on the 1 April 2016 was successfully attended by over 400 staff, collaborators and partners. The event offered the opportunity to share our vision, plan for training and highlight recent success stories.
The MRC Unit The Gambia (MRCG), has a long standing interest in tuberculosis (TB) occurring in households and has over the years maintained the TB research platform through core funding and a program grant focused on children with TB.
The MRC Unit The Gambia (MRCG) will be hosting a ‘Bridging Biobanking and Biomedical Research across Europe and Africa’ (B3Africa) international workshop from 11-13 April 2016 at Kairaba Hotel.
In an effort to improve our impact and position as a leader in health research and to address inconsistencies with the way our name and logo are used, we have revised our name to MRC Unit The Gambia (without a comma), which should be used in the first instance. We can also be referred to […]
The MRC Unit The Gambia (MRCG), is internationally recognised for delivering excellent global health research in Africa and beyond. Building on these achievements, for the next 5 years, MRCG will be launching the 2016-2021 Quinquennial (5 year strategic plan) on the 1 April 2016 at 11am at our main site in Fajara.
With the global efforts of reducing pneumococcal disease through widespread introduction of pneumococcal vaccines. Concerns have emerged on the potential increase of morbidity and mortality from S. aureus disease in rural Africa, and West Africa in particular where very high rates of carriage of S. pneumoniae have been reported.
The annual Mixed Methods in International Health Research (QMM) 2016 course, hosted by MRC Unit The Gambia successfully completed on Friday 26th February 2016.
A four-year study (2012-2015), led by the Belgian Institute of Tropical Medicine Antwerp (ITM) and coordinated by Professor Umberto D’Alessandro, shows four available antimalarial treatments are safe to use in pregnancy, providing sound scientific evidence on their use.